222 related articles for article (PubMed ID: 31199586)
1. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
[TBL] [Abstract][Full Text] [Related]
2. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
3. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
4. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
[TBL] [Abstract][Full Text] [Related]
5. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
6. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.
Robertson SJ; Pond GR; Hilton J; Petkiewicz SL; Ayroud Y; Kos Z; Gravel DH; Stober C; Vandermeer L; Arnaout A; Clemons M
Clin Breast Cancer; 2020 Feb; 20(1):61-67. PubMed ID: 31551182
[TBL] [Abstract][Full Text] [Related]
7. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
8. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
9. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
11. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
12. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
13. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
Walts AE; Mirocha JM; Bose S
Breast J; 2018 Nov; 24(6):951-956. PubMed ID: 30230113
[TBL] [Abstract][Full Text] [Related]
16. Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center.
Loggie J; Barnes PJ; Carter MD; Rayson D; Bethune GC
Breast; 2024 Jun; 75():103715. PubMed ID: 38520994
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
[TBL] [Abstract][Full Text] [Related]
19. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.
Slembrouck L; Vanden Bempt I; Wildiers H; Smeets A; Van Rompuy AS; Van Ongeval C; Jongen L; Weltens C; Punie K; Hoste G; Van Nieuwenhuysen E; Han S; Nevelsteen I; Neven P; Floris G
Mod Pathol; 2021 Jul; 34(7):1297-1309. PubMed ID: 33558657
[TBL] [Abstract][Full Text] [Related]
20. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
